Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Enzinger

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
Patient Education and Counseling|April 1, 2017
A stakeholder-driven approach to improve the informed consent process for palliative chemotherapyAndrea C Enzinger, Jennifer K Wind, Elizabeth Frank, et al.
European Journal of Radiology Open|December 11, 2020
Contribution of FDG-PET/CT to the management of esophageal cancer patients at multidisciplinary tumor board conferencesKumar K Shashi, Rachna Madan, Mark M Hammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Identification of potentially avoidable hospitalizations in patients with GI cancerGabriel A Brooks, Thomas A Abrams, Jeffrey A Meyerhardt, et al.
Virchows Archiv : an International Journal of Pathology|March 21, 2007
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinomaShuji Ogino, Jeffrey A Meyerhardt, Takako Kawasaki, et al.
Clinical Colorectal Cancer|October 10, 2006
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancerBrian M Wolpin, Jeffrey W Clark, Jeffrey A Meyerhardt, et al.
Cancer Investigation|October 10, 2003
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancerDavid P Ryan, Jeffrey W Clark, Matthew H Kulke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904Matthew H Kulke, Margaret A Tempero, Donna Niedzwiecki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapyJeffrey A Meyerhardt, Denise Heseltine, Hannia Campos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinomaAndrew X Zhu, Lawrence S Blaszkowsky, David P Ryan, et al.
Future Oncology (London, England)|May 2, 2024
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinomaJong-Mu Sun, Antoine Adenis, Peter C Enzinger, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
Patient Education and Counseling|April 1, 2017
A stakeholder-driven approach to improve the informed consent process for palliative chemotherapyAndrea C Enzinger, Jennifer K Wind, Elizabeth Frank, et al.
European Journal of Radiology Open|December 11, 2020
Contribution of FDG-PET/CT to the management of esophageal cancer patients at multidisciplinary tumor board conferencesKumar K Shashi, Rachna Madan, Mark M Hammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Identification of potentially avoidable hospitalizations in patients with GI cancerGabriel A Brooks, Thomas A Abrams, Jeffrey A Meyerhardt, et al.
Virchows Archiv : an International Journal of Pathology|March 21, 2007
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinomaShuji Ogino, Jeffrey A Meyerhardt, Takako Kawasaki, et al.
Clinical Colorectal Cancer|October 10, 2006
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancerBrian M Wolpin, Jeffrey W Clark, Jeffrey A Meyerhardt, et al.
Cancer Investigation|October 10, 2003
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancerDavid P Ryan, Jeffrey W Clark, Matthew H Kulke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904Matthew H Kulke, Margaret A Tempero, Donna Niedzwiecki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapyJeffrey A Meyerhardt, Denise Heseltine, Hannia Campos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinomaAndrew X Zhu, Lawrence S Blaszkowsky, David P Ryan, et al.
Future Oncology (London, England)|May 2, 2024
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinomaJong-Mu Sun, Antoine Adenis, Peter C Enzinger, et al.
Pageof 10